Sputnik Light Vaccine Demonstrates Safety and Effectiveness in Real-World

The Russian Direct Investment Fund (RDIF) announced Paraguay’s Ministry of Health data regarding the Sputnik Light vaccine. It demonstrated a high safety profile and a 93.5% efficacy, as reported during the ongoing vaccination campaign among more than 320,000 subjects in Paraguay.

The data also indicates no serious adverse events associated with vaccination or cases of myocarditis - pericarditis, amongst others.

Kirill Dmitriev, CEO of the RDIF, stated in a related press release issued on August 18, 2021, “The one-shot Sputnik Light vaccine enables authorities of Paraguay to speed up the vaccination of the population and accelerate the creation of herd immunity."

Furthermore, initial safety results of the world’s first study of a combination between Sputnik Light and the AstraZeneca vaccine in Azerbaijan demonstrates a high safety profile for the combined use of the vaccines with no serious adverse events or cases of coronavirus after vaccination.

Also, RDIF, Ministry of Health of Argentina, Ministry of Science of Argentina, and CONICET are conducting a study to evaluate the immune response and safety of heterogeneous regimens combining Sputnik Light and vaccines produced by COVID-19 vaccines from AstraZeneca, Sinopharm, and Moderna.

The Sputnik Light vaccine is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of the Sputnik V vaccine.

The Moscow-based Russian Direct Investment Fund is Russia's sovereign wealth fund established in 2011 to make equity co-investments alongside reputable international financial and strategic investors.